Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

UroGen Pharma Ltd. - Ordinary Shares (NQ:URGN)

21.89 -0.24 (-1.08%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 6, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	488,203
Open	22.00
Bid (Size)	21.83 (100)
Ask (Size)	22.30 (100)
Prev. Close	22.13
Today's Range	21.66 - 22.43
52wk Range	3.420 - 30.00
Shares Outstanding	36,130,121
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

January 05, 2026

From UroGen Pharma Ltd.

Via GlobeNewswire

Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗

December 26, 2025

A full exit after a monster rally says less about the company’s science and more about how disciplined funds lock in wins when portfolio math starts to matter.

Via The Motley Fool

Performance

YTD	-3.6%	-3.6%
1 Month	-5.2%	-5.2%
3 Month	+30.0%	+30.0%
6 Month	+59.7%	+59.7%
1 Year	+98.8%	+98.8%

More News

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

November 25, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen (URGN) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

Via The Motley Fool

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Q3 2025 Earnings: Revenue Misses, Loss Per Share Beats ↗

November 06, 2025

Via Chartmill

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

November 06, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

November 06, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

November 04, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

October 30, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

October 27, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

October 24, 2025

Via Benzinga

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

October 02, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 08, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Present at Upcoming Investor Conferences

August 21, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen (URGN) Q2 Revenue Rises 11% ↗

August 07, 2025

Via The Motley Fool

UROGEN PHARMA LTD (NASDAQ:URGN) Reports Mixed Q2 2025 Earnings Amid Widening Losses and Revenue Beat ↗

August 07, 2025

Via Chartmill

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

August 07, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 05, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

July 29, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit

July 28, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

July 28, 2025

From UroGen Pharma Ltd.

Via GlobeNewswire

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

July 21, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Frequently Asked Questions

Is UroGen Pharma Ltd. - Ordinary Shares publicly traded?

Yes, UroGen Pharma Ltd. - Ordinary Shares is publicly traded.

What exchange does UroGen Pharma Ltd. - Ordinary Shares trade on?

UroGen Pharma Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for UroGen Pharma Ltd. - Ordinary Shares?

The ticker symbol for UroGen Pharma Ltd. - Ordinary Shares is URGN on the Nasdaq Stock Market

What is the current price of UroGen Pharma Ltd. - Ordinary Shares?

The current price of UroGen Pharma Ltd. - Ordinary Shares is 21.89

When was UroGen Pharma Ltd. - Ordinary Shares last traded?

The last trade of UroGen Pharma Ltd. - Ordinary Shares was at 01/06/26 04:00 PM ET

What is the market capitalization of UroGen Pharma Ltd. - Ordinary Shares?

The market capitalization of UroGen Pharma Ltd. - Ordinary Shares is 790.89M

How many shares of UroGen Pharma Ltd. - Ordinary Shares are outstanding?

UroGen Pharma Ltd. - Ordinary Shares has 791M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.